Literature DB >> 27776677

From Long-Term Injecting to Long-Term Non-Injecting Heroin and Cocaine Use: The Persistence of Changed Drug Habits.

Don C Des Jarlais1, Kamyar Arasteh2, Jonathan Feelemyer2, Courtney McKnight2, David M Barnes2, Susan Tross3, David C Perlman2, Aimee N C Campbell3, Hannah L F Cooper4, Holly Hagan5.   

Abstract

OBJECTIVES: Transitioning from injecting to non-injecting routes of drug administration can provide important individual and community health benefits. We assessed characteristics of persons who had ceased injecting while continuing to use heroin and/or cocaine in New York City.
METHODS: We recruited subjects entering Mount Sinai Beth Israel detoxification and methadone maintenance programs between 2011 and 2015. Demographic information, drug use histories, sexual behaviors, and "reverse transitions" from injecting to non-injecting drug use were assessed in structured face-to-face interviews. There were 303 "former injectors," operationally defined as persons who had injected at some time in their lives, but had not injected in at least the previous 6 months. Serum samples were collected for HIV and HCV testing.
RESULTS: Former injectors were 81% male, 19% female, 17% White, 43% African-American, and 38% Latino/a, with a mean age of 50 (SD=9.2), and were currently using heroin and/or cocaine. They had injected drugs for a mean of 14 (SD=12.2) years before ceasing injection, and a mean of 13 (SD=12) years had elapsed since their last injection. HIV prevalence among the sample was 13% and HCV prevalence was 66%. The former injectors reported a wide variety of reasons for ceasing injecting. Half of the group appeared to have reached a point where relapse back to injecting was no longer problematic: they had not injected for three or more years, were not deliberately using specific techniques to avoid relapse to injecting, and were not worried about relapsing to injecting.
CONCLUSIONS: Former injectors report very-long term behavior change toward reduced individual and societal harm while continuing to use heroin and cocaine. The behavior change appears to be self-sustaining, with full replacement of an injecting route of drug administration by a non-injecting route of administration. Additional research on the process of long-term cessation of injecting should be conducted within a "combined prevention and care" approach to HIV and HCV infection among persons who use drugs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Former-injectors; HIV; Hepatitis C; Non-injection drugs use; Relapse

Mesh:

Year:  2016        PMID: 27776677      PMCID: PMC5117630          DOI: 10.1016/j.jsat.2016.08.015

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  23 in total

1.  Stigma, discrimination and the health of illicit drug users.

Authors:  Jennifer Ahern; Jennifer Stuber; Sandro Galea
Journal:  Drug Alcohol Depend       Date:  2006-11-21       Impact factor: 4.492

2.  Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study.

Authors:  Marcel C A Buster; Ewald Witteveen; Maria Prins; Erik J C van Ameijden; Gerard Schippers; Anneke Krol
Journal:  Eur Addict Res       Date:  2009-07-20       Impact factor: 3.015

3.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Authors:  D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky
Journal:  JAMA       Date:  1989-02-17       Impact factor: 56.272

4.  Role of sexual transmission of HIV among young noninjection and injection opiate users: a respondent-driven sampling study.

Authors:  Jian Li; Hongjie Liu; Jianhua Li; Jian Luo; Don Des Jarlais; Nana Koram
Journal:  Sex Transm Dis       Date:  2011-12       Impact factor: 2.830

5.  Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users.

Authors:  Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2006-09-07       Impact factor: 4.492

6.  Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland.

Authors:  Becky L Genberg; Stephen J Gange; Vivian F Go; David D Celentano; Gregory D Kirk; Shruti H Mehta
Journal:  Am J Epidemiol       Date:  2011-02-13       Impact factor: 4.897

7.  Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users.

Authors:  I J Spijkerman; E J van Ameijden; G H Mientjes; R A Coutinho; A van den Hoek
Journal:  J Clin Epidemiol       Date:  1996-10       Impact factor: 6.437

Review 8.  Relapse prevention for alcohol and drug problems: that was Zen, this is Tao.

Authors:  Katie Witkiewitz; G Alan Marlatt
Journal:  Am Psychol       Date:  2004 May-Jun

9.  Decline in intravenous drug use among treatment-seeking opiate users.

Authors:  R S Schottenfeld; S O'Malley; K Abdul-Salaam; P G O'Connor
Journal:  J Subst Abuse Treat       Date:  1993 Jan-Feb

10.  Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.

Authors:  Ingrid A Binswanger; Carolyn Nowels; Karen F Corsi; Jason Glanz; Jeremy Long; Robert E Booth; John F Steiner
Journal:  Addict Sci Clin Pract       Date:  2012-03-15
View more
  2 in total

1.  Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study.

Authors:  William C Goedel; Maximilian R F King; Mark N Lurie; Sandro Galea; Jeffrey P Townsend; Alison P Galvani; Samuel R Friedman; Brandon D L Marshall
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

2.  Injecting drug use opportunities and reasons for choosing not to inject: A population-based study of Australian young adults who use stimulants.

Authors:  Luke Edward Casey; Davoud Pourmarzi; Ellen Leslie Wessel; Robert Kemp; Andrew Smirnov
Journal:  Drug Alcohol Rev       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.